IHV01

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), U.S. Army Medical Research and Development Command

Conditions

HIVHIV Infections

Phase 1

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

WithdrawnNCT03505060

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2019-01-01End: 2019-11-11Updated: 2021-10-15

HIV Vaccine in HIV-uninfected Adults

CompletedNCT04658667

U.S. Army Medical Research and Development CommandHIV

Start: 2022-02-03End: 2024-07-01Updated: 2025-07-30